Paradigm Therapeutics
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa (NCT07482787) | Paradigm Therapeutics | 2026-07-21 |
| An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa (NCT07482813) | Paradigm Therapeutics | 2026-07-15 |
Track Paradigm Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.